Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study

Sara Nysom Christiansen; Simon Horskjær Rasmussen; Mikkel Ostergaard; Marion Pons; Brigitte Michelsen; Karel Pavelka; Catalin Codreanu; Adrian Ciurea; Bente Glintborg; Maria Jose Santos; Ismail Sari; Ziga Rotar; Bjorn Gudbjornsson; Gary J Macfarlane; Heikki Relas; Florenzo Iannone; Karin Laas; Johan K Wallman; Marleen van de Sande; Sella Aarrestad Provan; Isabel Castrejon; Jakub Zavada; Corina Mogosan; Michael J Nissen; Anne Gitte Loft; Anabela Barcelos; Yesim Erez; Katja Perdan Pirkmajer; Gerdur Grondal; Gareth T Jones; Anna-Mari Hokkanen; Maria Sole Chimenti; Sigrid Vorobjov; Daniela Di Giuseppe; Tore K Kvien; Lucia Otero-Varela; Irene van der Horst-Bruinsma; Merete Lund Hetland; Lykke Midtbøll Ørnbjerg

Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study

Sara Nysom Christiansen^*, Simon Horskjær Rasmussen, Mikkel Ostergaard, Marion Pons, Brigitte Michelsen, Karel Pavelka, Catalin Codreanu, Adrian Ciurea, Bente Glintborg, Maria Jose Santos, Ismail Sari, Ziga Rotar, Bjorn Gudbjornsson, Gary J Macfarlane, Heikki Relas, Florenzo Iannone, Karin Laas, Johan K Wallman, Marleen van de Sande, Sella Aarrestad ProvanIsabel Castrejon, Jakub Zavada, Corina Mogosan, Michael J Nissen, Anne Gitte Loft, Anabela Barcelos, Yesim Erez, Katja Perdan Pirkmajer, Gerdur Grondal, Gareth T Jones, Anna-Mari Hokkanen, Maria Sole Chimenti, Sigrid Vorobjov, Daniela Di Giuseppe, Tore K Kvien, Lucia Otero-Varela, Irene van der Horst-Bruinsma, Merete Lund Hetland, Lykke Midtbøll Ørnbjerg

^*Corresponding author for this work

Department for Rheumatology and Spine Diseases

Abstract

OBJECTIVES: To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe.

METHODS: Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries.Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0-10), for example, pain ≤2/Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated.Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/adjusted for multiple confounders).

RESULTS: Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar.During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%).However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates.

CONCLUSION: Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.

Original language	English
Article number	e004166
Journal	RMD Open
Volume	10
Issue number	3
ISSN	2056-5933
Publication status	Published - 24 Jul 2024

Keywords

Humans
Male
Antibodies, Monoclonal, Humanized/therapeutic use
Female
Adult
Treatment Outcome
Europe
Middle Aged
Axial Spondyloarthritis/drug therapy
Antirheumatic Agents/therapeutic use
Prospective Studies
Severity of Illness Index
Patient Reported Outcome Measures
Radiography
Remission Induction

Cite this

Christiansen, S. N., Horskjær Rasmussen, S., Ostergaard, M., Pons, M., Michelsen, B., Pavelka, K., Codreanu, C., Ciurea, A., Glintborg, B., Santos, M. J., Sari, I., Rotar, Z., Gudbjornsson, B., Macfarlane, G. J., Relas, H., Iannone, F., Laas, K., Wallman, J. K., van de Sande, M., ... Ørnbjerg, L. M. (2024). Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study. RMD Open, 10(3), Article e004166.

Christiansen, SN, Horskjær Rasmussen, S, Ostergaard, M , Pons, M , Michelsen, B, Pavelka, K, Codreanu, C, Ciurea, A, Glintborg, B, Santos, MJ, Sari, I, Rotar, Z, Gudbjornsson, B, Macfarlane, GJ, Relas, H, Iannone, F, Laas, K, Wallman, JK, van de Sande, M, Provan, SA, Castrejon, I, Zavada, J, Mogosan, C, Nissen, MJ, Loft, AG, Barcelos, A, Erez, Y, Pirkmajer, KP, Grondal, G, Jones, GT, Hokkanen, A-M, Chimenti, MS, Vorobjov, S, Di Giuseppe, D, Kvien, TK, Otero-Varela, L, van der Horst-Bruinsma, I, Hetland, ML & Ørnbjerg, LM 2024, 'Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study', RMD Open, vol. 10, no. 3, e004166.

@article{8aa426eb1dd44d9682c83690e7eeaa23,

title = "Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study",

abstract = "OBJECTIVES: To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe.METHODS: Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries.Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0-10), for example, pain ≤2/Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated.Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/adjusted for multiple confounders).RESULTS: Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar.During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%).However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates.CONCLUSION: Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.",

keywords = "Humans, Male, Antibodies, Monoclonal, Humanized/therapeutic use, Female, Adult, Treatment Outcome, Europe, Middle Aged, Axial Spondyloarthritis/drug therapy, Antirheumatic Agents/therapeutic use, Prospective Studies, Severity of Illness Index, Patient Reported Outcome Measures, Radiography, Remission Induction",

author = "Christiansen, {Sara Nysom} and {Horskj{\ae}r Rasmussen}, Simon and Mikkel Ostergaard and Marion Pons and Brigitte Michelsen and Karel Pavelka and Catalin Codreanu and Adrian Ciurea and Bente Glintborg and Santos, {Maria Jose} and Ismail Sari and Ziga Rotar and Bjorn Gudbjornsson and Macfarlane, {Gary J} and Heikki Relas and Florenzo Iannone and Karin Laas and Wallman, {Johan K} and {van de Sande}, Marleen and Provan, {Sella Aarrestad} and Isabel Castrejon and Jakub Zavada and Corina Mogosan and Nissen, {Michael J} and Loft, {Anne Gitte} and Anabela Barcelos and Yesim Erez and Pirkmajer, {Katja Perdan} and Gerdur Grondal and Jones, {Gareth T} and Anna-Mari Hokkanen and Chimenti, {Maria Sole} and Sigrid Vorobjov and {Di Giuseppe}, Daniela and Kvien, {Tore K} and Lucia Otero-Varela and {van der Horst-Bruinsma}, Irene and Hetland, {Merete Lund} and {\O}rnbjerg, {Lykke Midtb{\o}ll}",

note = "{\textcopyright} Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",

year = "2024",

month = jul,

day = "24",

language = "English",

volume = "10",

journal = "RMD Open",

issn = "2056-5933",

publisher = "BMJ Publishing Group",

number = "3",

}

TY - JOUR

T1 - Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis

T2 - a European routine-care observational study

AU - Christiansen, Sara Nysom

AU - Horskjær Rasmussen, Simon

AU - Ostergaard, Mikkel

AU - Pons, Marion

AU - Michelsen, Brigitte

AU - Pavelka, Karel

AU - Codreanu, Catalin

AU - Ciurea, Adrian

AU - Glintborg, Bente

AU - Santos, Maria Jose

AU - Sari, Ismail

AU - Rotar, Ziga

AU - Gudbjornsson, Bjorn

AU - Macfarlane, Gary J

AU - Relas, Heikki

AU - Iannone, Florenzo

AU - Laas, Karin

AU - Wallman, Johan K

AU - van de Sande, Marleen

AU - Provan, Sella Aarrestad

AU - Castrejon, Isabel

AU - Zavada, Jakub

AU - Mogosan, Corina

AU - Nissen, Michael J

AU - Loft, Anne Gitte

AU - Barcelos, Anabela

AU - Erez, Yesim

AU - Pirkmajer, Katja Perdan

AU - Grondal, Gerdur

AU - Jones, Gareth T

AU - Hokkanen, Anna-Mari

AU - Chimenti, Maria Sole

AU - Vorobjov, Sigrid

AU - Di Giuseppe, Daniela

AU - Kvien, Tore K

AU - Otero-Varela, Lucia

AU - van der Horst-Bruinsma, Irene

AU - Hetland, Merete Lund

AU - Ørnbjerg, Lykke Midtbøll

PY - 2024/7/24

Y1 - 2024/7/24

N2 - OBJECTIVES: To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe.METHODS: Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries.Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0-10), for example, pain ≤2/Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated.Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/adjusted for multiple confounders).RESULTS: Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar.During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%).However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates.CONCLUSION: Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.

AB - OBJECTIVES: To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe.METHODS: Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries.Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0-10), for example, pain ≤2/Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated.Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/adjusted for multiple confounders).RESULTS: Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar.During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%).However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates.CONCLUSION: Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.

KW - Humans

KW - Male

KW - Antibodies, Monoclonal, Humanized/therapeutic use

KW - Female

KW - Adult

KW - Treatment Outcome

KW - Europe

KW - Middle Aged

KW - Axial Spondyloarthritis/drug therapy

KW - Antirheumatic Agents/therapeutic use

KW - Prospective Studies

KW - Severity of Illness Index

KW - Patient Reported Outcome Measures

KW - Radiography

KW - Remission Induction

UR - http://www.scopus.com/inward/record.url?scp=85199661747&partnerID=8YFLogxK

M3 - Journal article

C2 - 39053949

SN - 2056-5933

VL - 10

JO - RMD Open

JF - RMD Open

IS - 3

M1 - e004166

ER -

Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study

Abstract

Keywords

Other files and links

Fingerprint

Cite this